Shailendra Giri, PhDMayo Clinic S-nitrosylation mediated inactiviation of TSG in ovarian cancer Chronic inflammation has become a well-accepted risk factor for epithelial-derived malignancies, including ovarian cancer. But how inflammation contributes to the process of carcinogenesis is a grey area. If successful, Dr. Giri’s study will elucidate the possible novel regulation of chemical inactivation of LKB1-AMPK […]
Read More
Elda Righi, MDMassachusetts General Hospital Blockade of the CXCL12 and VEGF axes in ovarian cancer One of the reasons ovarian cancer progresses with few evident symptoms may be the combination of ways in which the cancer escapes the patient’s immune system and organizes a vascular supply to serve its own needs. CXCL12 and VEGF are […]
Read More
Amelie Margarete Lutz, MD, PhDStanford University2009 Gilman Family Scholar Early Detection of Ovarian Cancer Using Targeted Microbubble-Enhanced Ultrasound The primary objective of Dr. Lutz’s proposal is to validate and refine molecularly targeted microbubble contrast enhanced ultrasound (CEUS) for non-invasive, in-vivo imaging of the ovarian cancer-related angiogenesis. Like other solid tumors, ovarian cancer is critically dependent […]
Read More
Xiaohong (Mary) Zhang, PhDUniversity of South Florida, College of Medicine Mechanisms by which HDAC inhibitors sensitize cisplatin resistant ovarian cells Overcoming platinum-resistance in ovarian cancer patients remains a great challenge. Recently, histone deacetylase (HDAC) inhibitors are being used to minimize resistance. HDAC6 may confer the cisplatin-resistance by down-regulating a DNA repair complex. Dr. Zhang will […]
Read More
Elizabeth Swisher, MDUniversity of Washington Falloposcopy: A Novel Approach to Ovarian Cancer Detection and Prevention Recent data suggest that many presumed ovarian or peritoneal carcinomas may actually arise in the fallopian tubes (FT). If true, early detection of ovarian carcinoma should focus on viewing and sampling the FT. A new technology has been developed at […]
Read More
Thomas Spies, PhDFred Hutchinson Cancer Research Center Survival Signaling by the NKG2D Immunoreceptor in Ovarian Cancer Cancers adopt diverse strategies for immune evasion to safeguard their survival. The activating immunoreceptor NKG2D and its tumor-associated ligand MICA are key components in the human lymphocyte defense against cancer. Dr. Spies has discovered that solid tumors including ovarian […]
Read More
Anna deFazio, BSc (Hons), PhDUniversity of Sydney Ovulation-Related Gene Expression Signature Dysregulated in Progression to Cancer Women with a higher number of ovulations throughout their lifetime, without breaks due to pregnancy or oral contraceptives, have increased ovarian cancer risk. Dr. deFazio’s study aims to identify the genes that participate in the ovulation process in normal […]
Read More
Christine Messineo Annunziata, MD, PhDNational Cancer Institute Investigation of Genetic Alterations Promoting NF-kB in ovarian cancer Nuclear Factor kappa B (NF-kB) is a family of proteins that regulate the levels of genes involved in cell growth and survival and are present in many different types of cells. Dr. Annunziata’s research completed under a MRC Scientific […]
Read More
M. Robyn Andersen, PhDFred Hutchinson Cancer Research Center Use of counter-indicated CAM treatments by ovarian cancer patients It has been estimated that 44% of ovarian cancer patients use Complementary and Alternative Medicine (CAM). While many CAM treatments are safe, several that may be commonly used are contra-indicated during active conventional treatment. Dr. Anderson’s study seeks […]
Read More